• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    65 Biggest Movers From Yesterday

    1/19/22 4:45:39 AM ET
    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Professional Services
    Consumer Discretionary
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AGIL alert in real time by email

    Gainers

    • Brickell Biotech, Inc. (NASDAQ:BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and $2 price target.
    • DatChat, Inc. (NASDAQ:DATS) surged 38.8% to settle at $3.33 on Tuesday. DatChat initiated Web 3.0 platform development for protection of NFTs and encrypted messaging.
    • Indonesia Energy Corporation Limited (NYSE:INDO) gained 31.1% to close at $4.30.
    • NeuroMetrix, Inc. (NASDAQ:NURO) shares surged 29.5% to close at $6.37 on Tuesday after the company eeceived FDA Breakthrough Device Designation for the treatment of chronic chemo induced peripheral neuropathy with its wearable neurostimulation technology.
    • Mainz Biomed B.V. (NASDAQ:MYNZ) gained 27.9% to close at $26.69 after jumping 27% on Friday.
    • Vinco Ventures, Inc. (NASDAQ:BBIG) gained 27.5% to close at $5.19 following a 15% surge on Friday.
    • Activision Blizzard, Inc. (NASDAQ:ATVI) surged 25.9% to settle at $82.31. Microsoft on Tuesday announced that it plans to acquire game developer and interactive entertainment content publisher Activision Blizzard for $95 per share in an all-cash transaction valued at $68.7 billion.
    • Immuron Limited (NASDAQ:IMRN) gained 24.8% to close at $4.23. Immuron recently received AUD $306,154 R&D tax concession refund for 2021 financial year.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) rose 21.8% to settle at $86.31.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) gained 20.3% to close at $4.21 after EH Hutton initiated coverage on the stock with a Buy rating and a $6 price target.
    • Integrated Media Technology Limited (NASDAQ:IMTE) jumped 20% to settle at $10.52 after the company announced the completion of the development of its online digital assets trading platform "Ouction."
    • InnSuites Hospitality Trust (NYSE:IHT) gained 18.3% to settle at $3.55.
    • ReTo Eco-Solutions, Inc. (NASDAQ:RETO) surged 18% to close at $1.77. ReTo Eco-Solutions recently entered into an Equity Acquisition Agreement with Hainan REIT Mingde Investment Holding Co.
    • Insignia Systems, Inc. (NASDAQ:ISIG) surged 17.5% to close at $22.79 after declining around 14% on Friday.
    • OncoCyte Corporation (NASDAQ:OCX) gained 15.9% to settle at $2.19. Oncocyte reported development and co-marketing agreement with Thermo Fisher Scientific to expand access to precision oncology.
    • AgileThought, Inc. (NASDAQ:AGIL) gained 15.6% to settle at $5.42.
    • Cardiol Therapeutics Inc. (NASDAQ:CRDL) surged 15.5% to close at $2.31.
    • Vaxxinity, Inc. (NASDAQ:VAXX) jumped 14.3% to close at $7.36. Vaxxinity recently announced the first Parkinson's disease patient has been dosed in Part B of a Phase 1 clinical trial of UB-312.
    • SG Blocks, Inc. (NASDAQ:SGBX) gained 14.2% to settle at $2.17.
    • ION Geophysical Corporation (NYSE:IO) shares jumped 11.4% to close at $0.9465 after the company reported forbearance and amendment related to its revolving credit agreement, forbearance agreement related to its senior secured second priority notes due 2025. The company also reported preliminary Q4 revenues of $40 million, representing a 45% year-over-year surge.
    • Pluristem Therapeutics Inc. (NASDAQ:PSTI) jumped 10.9% to close at $2.14 after jumping 10% on Friday. Pluristem Therapeutics and Tnuva recently announced a collaboration to establish a cultured food platform.
    • Houghton Mifflin Harcourt Company (NASDAQ:HMHC) jumped 9.7% to close at $17.73.
    • National CineMedia, Inc. (NASDAQ:NCMI) gained 9.1% to settle at $2.99.
    • New Concept Energy, Inc. (NYSE:GBR) gained 7.6% to close at $2.69.
    • QuickLogic Corporation (NASDAQ:QUIK) gained 4.5% to close at $5.39. QuickLogic reported preliminary selected financial results for its fourth fiscal quarter, ending January 2, 2022.


    Check out these big penny stock gainers and losers

    Losers

    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares tumbled 58.8% to close at $0.2216 on Tuesday after the company priced a $3.5 million underwritten public offering of ordinary shares.
    • BIT Mining Limited (NYSE:BTCM) fell 32.4% to close at $3.32.
    • Guardforce AI Co., Limited (NASDAQ:GFAI) dipped 29% to settle at $1.15 after the company announced pricing of a $10.3 million offering.
    • East Stone Acquisition Corporation (NASDAQ:ESSC) shares declined 28.2% to close at $11.16.
    • GWG Holdings, Inc. (NASDAQ:GWGH) fell 28% to settle at $5.65.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) dipped 27.3% to close at $5.02. Revelation Biosciences said first patient was enrolled and dosed in Phase 1b clinical study of REVTx-99 for the treatment of allergic rhinitis.
    • Silvergate Capital Corporation (NYSE:SI) dropped 25.2% to close at $103.34 after the company reported worse-than-expected Q4 EPS results.
    • Splash Beverage Group, Inc. (NYSE:SBEV) shares fell 22.3% to close at $3.25 after jumping around 119% on Friday.
    • Seer, Inc. (NASDAQ:SEER) fell 20.4% to close at $15.59.
    • SOPHiA GENETICS SA (NASDAQ:SOPH) dipped 19.7% to settle at $11.35.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) dropped 18.8% to close at $7.41.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) tumbled 18.7% to settle at $27.21. Arcturus Therapeutics, last month, reported preliminary data which shows an increase in neutralizing antibody geometric mean concentration against SARS-CoV-2.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) fell 18.3% to close at $7.38. HC Wainwright & Co. recently initiated coverage on Biomea Fusion with a Buy rating and announced a price target of $13.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) dropped 18% to close at $1.00.
    • Rain Therapeutics Inc. (NASDAQ:RAIN) dipped 17.8% to close at $9.81.
    • Praxis Precision Medicines, Inc. (NASDAQ:PRAX) dropped 17.5% to settle at $14.46. Praxis Precision Medicines highlighted publication of preclinical data highlighting 'Differentiated and Potent Antiepileptic Activity of PRAX-562.'
    • OneSmart International Education Group Limited (NYSE:ONE) fell 17.4% to close at $0.1546 after declining over 5% on Friday..
    • Galera Therapeutics, Inc. (NASDAQ:GRTX) fell 17.2% to close at $2.85.
    • Clever Leaves Holdings Inc. (NASDAQ:CLVR) dropped 17% to close at $2.29.
    • Molecular Partners AG (NASDAQ:MOLN) shares fell 16.9% to settle at $26.50. Molecular Partners finalized license agreement with Novartis for Ensovibep for COVID-19.
    • Sonendo, Inc. (NYSE:SONX) shares fell 16.9% to close at $6.79.
    • RAPT Therapeutics, Inc. (NASDAQ:RAPT) dropped 16.4% to settle at $24.75.
    • Akouos, Inc. (NASDAQ:AKUS) fell 15.8% to close at $6.93.
    • Ipsidy Inc. (NASDAQ:AUID) dipped 15.4% to settle at $8.22.
    • Solo Brands, Inc. (NYSE:DTC) fell 14.6% to close at $13.61.
    • OceanPal Inc. (NASDAQ:OP) dropped 14.5% to close at $1.53.
    • Unilever PLC (NYSE:UL) fell 14.4% to settle at $46.45. GlaxoSmithKline received three proposals from Unilever for its Consumer business. However, Glaxo rejected all three offers from the company.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) dipped 14.4% to close at $19.89.
    • Surrozen, Inc. (NASDAQ:SRZN) dropped 13.8% to settle at $4.00.
    • Dyne Therapeutics, Inc. (NASDAQ:DYN) fell 12.6% to close at $8.12. The FDA placed a clinical hold on Dyne Therapeutics investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.
    • Cognition Therapeutics, Inc. (NASDAQ:CGTX) shares fell 12.2% to settle at $5.49.
    • Select Medical Holdings Corporation (NYSE:SEM) fell 12.1% to close at $25.42. RBC Capital and B of A Securities lowered price targets on the stock.
    • Poshmark, Inc. (NASDAQ:POSH) shares fell 10.7% to close at $15.17.
    • Largo Inc. (NASDAQ:LGO) fell 10.4% to close at $9.25.
    • Mechel PAO (NYSE:MTL) shares fell 10.4% to close at $2.83.
    • Sweetgreen, Inc. (NYSE:SG) shares fell 9.7% to close at $23.68.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) fell 9% to close at $8.19. Allarity Therapeutics and Oncoheroes Biosciences recently entered into licensing agreements for Allarity's dovitinib and stenoparib for further clinical development in pediatric cancers.
    • Brilliant Earth Group, Inc. (NASDAQ:BRLT) shares fell 8.1% to close at $11.41.
    • R. R. Donnelley & Sons Company (NYSE:RRD) fell 7% to close at $10.45.
    • Camber Energy, Inc. (NYSE:CEI) shares fell 5.6% to close at $0.7071. Camber Energy recently received a letter from the NYSE American.
    Get the next $AGIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIL
    $AKUS
    $ALLR
    $ARCT

    CompanyDatePrice TargetRatingAnalyst
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    1/23/2026$20.00Buy
    Roth Capital
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    RAPT Therapeutics Inc.
    $RAPT
    1/9/2026$95.00Overweight
    Piper Sandler
    Unilever PLC
    $UL
    1/8/2026$71.00Outperform → Neutral
    BNP Paribas Exane
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Sweetgreen Inc.
    $SG
    1/6/2026$7.50Buy → Neutral
    UBS
    More analyst ratings

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Molecular Partners AG with a new price target

    H.C. Wainwright initiated coverage of Molecular Partners AG with a rating of Buy and set a new price target of $13.00

    1/27/26 8:47:34 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Revelation Biosciences Inc.

    PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/6/26 4:32:19 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biomea Fusion Inc.

    SCHEDULE 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

    2/6/26 4:30:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Rain Enhancement Technologies Holdco Inc.

    SCHEDULE 13G - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Subject)

    2/6/26 2:30:22 PM ET
    $RAIN
    Industrial Machinery/Components
    Technology

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Erdtmann Rainer M decreased direct ownership by 21% to 572,427 units (SEC Form 5)

    5 - Biomea Fusion, Inc. (0001840439) (Issuer)

    2/6/26 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT & CFO Horn David R. was granted 79,000 shares, increasing direct ownership by 18% to 509,005 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/5/26 6:54:29 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO AND CHAIR Farokhzad Omid was granted 697,162 shares, increasing direct ownership by 26% to 3,373,449 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/5/26 6:52:23 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Column Group Iii Gp, Lp bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:35:33 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kutzkey Tim bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:31:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th

    2/5/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation at 1:30 PM Eastern Time / 10:30 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surr

    2/5/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sweetgreen is "Here For The Bowl"

    Ahead of The Big Game, The Brand Unveils a Larger-Than-Life San Francisco Activation Celebrating Its New Catering Offering Ahead of The Big Game, Sweetgreen is making a bold statement in San Francisco and inviting fans to see it for themselves, unveiling a larger-than-life "Here for the Bowl" activation in celebration of the launch of the brand's newest catering format: the Build Your Own Sweetgreen Bar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205790283/en/Now available nationwide at select locations, the Build Your Own Sweetgreen Bar is Sweetgreen's most flexible catering format to date. On Saturday, February 7, fro

    2/5/26 9:00:00 AM ET
    $SG
    Restaurants
    Consumer Discretionary

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

    SC 13G/A - Oncocyte Corp (0001642380) (Subject)

    12/9/24 5:30:06 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by ReTo Eco-Solutions Inc.

    SC 13G/A - ReTo Eco-Solutions, Inc. (0001687277) (Subject)

    12/3/24 8:32:02 AM ET
    $RETO
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by ReTo Eco-Solutions Inc.

    SC 13G/A - ReTo Eco-Solutions, Inc. (0001687277) (Subject)

    12/3/24 8:31:02 AM ET
    $RETO
    Industrial Machinery/Components
    Industrials

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Leadership Updates

    Live Leadership Updates

    View All

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AKUS
    $ALLR
    $ARCT
    Financials

    Live finance-specific insights

    View All

    Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th

    2/5/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    QuickLogic to Report Fourth Quarter and Full Year Fiscal 2025 Financial Results on Tuesday, March 3

    SAN JOSE, Calif., Feb. 5, 2026 /PRNewswire/ -- QuickLogic Corporation (NASDAQ:QUIK), a developer of embedded FPGA (eFPGA) IP and ruggedized FPGAs and Endpoint AI solutions, today announced that it has scheduled a conference call to discuss its fourth quarter and full year fiscal 2025 financial results on Tuesday, March 3, 2026. Date: Tuesday, March 3, 2026Time: 5:30 p.m. ET/2:30 p.m. PTDial-in: Toll Free: 1-877-407-0792; International: 1-201-689-8263Passcode: No passcode neededReplay: (844) 512-2921; Passcode: 13758490Duration: Through March 10, 2026 A webcast of the conferenc

    2/5/26 8:04:00 AM ET
    $QUIK
    Semiconductors
    Technology

    Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

    Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve

    2/2/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care